No annual revenue total was found in AEON Biopharma, Inc.'s SEC filings.
AEON Biopharma, Inc. (AEON) files with the SEC under industry code 2834, Pharmaceutical Preparations. Free cash flow was -$17.3 million. As of Jun 30, 2026 it held $3.4 million in cash and investments and $1.0 million in total debt.
Revenue
—
Net income (TTM)
$-54.62M
-3238.8% vs year-ago TTM
Operating cash flow (TTM)
$-13.64M
-0.5% vs year-ago TTM
Free cash flow
$-17.31M
+51.8% vs prior year
EPS (TTM)
$-1.91
-390.0% vs year-ago TTM
Dividend per share
None
Shares outstanding
25.30M
+140.2% vs prior year
Net cash
$2.41M
as of Jun 30, 2026
Operating margin
—
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- AEON (NYSE)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Aliso Viejo, CA
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1837607
- Former names
- Priveterra Acquisition Corp. (until Jul 24, 2023)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|
| Operating income | -$12.8M | $73.0M | -$48.4M | -$1.9M |
| Net income | -$39.2M | $42.0M | -$52.6M | $8.2M |
| Diluted EPS | -$3.95 | $72.93 | -$0.38 | — |
| Operating cash flow | -$17.3M | -$20.3M | -$35.6M | -$1.5M |
| Free cash flow | -$17.3M | — | -$35.9M | — |
| Total assets | $5.6M | $3.1M | $10.8M | $276.9M |
| Total liabilities | $60.6M | $31.7M | $143.2M | $17.9M |
| Stockholders' equity | -$55.0M | -$28.6M | — | — |
| Cash and investments | $3.0M | $13,000 | — | $497,412 |
| Total debt | $1.1M | $1.3M | $242,000 | — |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Material agreement
|
Nov 3, 2026 | Nov 2, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Oct 23, 2026 | Oct 23, 2026 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Sep 30, 2026 | Sep 30, 2026 |
| 10-Q | Quarterly report | Aug 12, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
Aug 12, 2026 | Aug 12, 2026 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Aug 3, 2026 | Aug 3, 2026 |
All 361 AEON Biopharma, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.